• Romark Initiates Phase 3 Clinical Trials Of NT-300 for COVID-19 americanpharmaceuticalreview
    April 30, 2020
    Romark will initiate two clinical trials of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) for prevention of COVID-19 and other viral respiratory illnesses in high-risk populations.
PharmaSources Customer Service